Business
EU signs joint procurement deal for Eli Lilly COVID-19 treatment
Published by maria gbaf
Posted on September 22, 2021
1 min readLast updated: February 3, 2026
Global Banking & Finance Review®
Company
Published by maria gbaf
Posted on September 22, 2021
1 min readLast updated: February 3, 2026
The EU has signed a contract with Eli Lilly for a COVID-19 treatment, involving 18 countries and aiming to treat up to 220,000 patients.
BRUSSELS (Reuters) – The European Commission has signed a joint procurement contract with U.S. drugmaker Eli Lilly and Co for the supply of a monoclonal antibody treatment for COVID-19, the EU executive arm said in a statement on Tuesday.
The treatment is under review by the European Medicines Agency, it said, and 18 EU countries have signed up to the joint procurement for the purchase of enough to treat up to 220,000 patients.
The deal is part of a portfolio of five promising therapeutics announced by the Commission under the EU’s COVID-19 Therapeutics Strategy in June. It also includes treatments from GlaxoSmithKline Plc and Vir Biotechnology Inc, Regeneron Pharmaceuticals Inc and Celltrion HealthCare Co.
“We need to continue our work to prevent illness with vaccines and at the same time ensure that we can treat it with therapeutics,” EU Commissioner for Health Stella Kyriakides said.
(Reporting by Jan Strupczewski; Editing by Bill Berkrot)
The main topic is the EU's procurement deal with Eli Lilly for a COVID-19 treatment.
It is a strategy by the EU to secure promising COVID-19 treatments, including those from Eli Lilly and other companies.
18 EU countries have signed up for the joint procurement.
Explore more articles in the Business category
